phrykt

Vir Biotechnology, Inc. (VIR): who owns it and who trades it

As of Nov 16, 2026, VIR insiders reported 33 open-market sales worth $8.2M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was SVF Endurance (Cayman) Ltd (10% owner), with $4.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Vir Biotechnology

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VIR

235 funds and institutions reported VIR shares worth $1.5B at the end of Q2 2026, about 88% of the company. The largest holder is BlackRock, Inc. with 12.3%.

Funds and institutions (13F) 88%Everyone else 12%

10 largest owners, by share of the company

BlackRock, Inc.12.3%
ARCH Venture Management, LLC7.5%
Vanguard Portfolio Management LLC6.8%
Sb Investment Advisers (uk) Ltd6.5%
State Street Corp5.9%
GSK plc5.1%
Vanguard Capital Management LLC3.8%
Point72 Asset Management, L.P.3.4%
Geode Capital Management, LLC2.0%
Dimensional Fund Advisors LP1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.20.68M12.26%$211M+15%
ARCH Venture Management, LLC12.69M7.53%$129M-2%
Vanguard Portfolio Management LLC11.50M6.82%$117M+25%
Sb Investment Advisers (uk) Ltd10.95M6.49%$112MNo change
State Street Corp9.96M5.91%$102M+40%
GSK plc8.55M5.07%$87.1MNo change
Vanguard Capital Management LLC6.39M3.79%$65.1M+19%
Point72 Asset Management, L.P.5.67M3.36%$57.7M+190%
Geode Capital Management, LLC3.35M1.99%$34.1M+26%
Dimensional Fund Advisors LP3.12M1.85%$31.8M+21%
ADAR1 Capital Management, LLC2.46M1.46%$25M-10%
Goldman Sachs Group Inc2.37M1.40%$24.1M-27%
FMR LLC (Fidelity)2.32M1.37%$23.6M+12%
Morgan Stanley2.21M1.31%$22.5M-23%
Nuveen, LLC1.98M1.18%$20.2M+95%
Pictet Asset Management Holding SA1.95M1.16%$19.9M+32%
Boxer Capital Management, LLC1.87M1.11%$19MNo change
Northern Trust Corp1.43M0.85%$14.6M+45%
Hudson Bay Capital Management LP1.36M0.81%$13.9M-7%
GordonMD Global Investments LP1.35M0.80%$13.8M-11%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VIR insiders reported $0 of open-market purchases and $8.2M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$8.2M
33 trades, 9 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 4, 2026

Purchases and sales by month

$1.3M$1.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026Verneuil Vanina deVice presidentSale plan2,407$11.10$26.7KForm 4
Nov 2, 2026Verneuil Vanina deVice presidentSale plan1,343$11.33$15.2KForm 4
Jun 1, 2026Janet NapolitanoDirectorSale plan3,200$9.45$30.2KForm 4
Jun 1, 2026Brent SabatiniVice presidentSale plan379$9.45$3.6KForm 4
May 1, 2026Vicki L SatoDirectorSale plan22,000$10.05$221KForm 4
Apr 6, 2026Backer Marianne DeCEOSale plan72,559$9.16$665KForm 4
Apr 1, 2026Vicki L SatoDirectorSale plan22,000$9.07$200KForm 4
Mar 23, 2026Brent SabatiniVice presidentSale plan7,711$9.12$70.3KForm 4
Mar 2, 2026Vicki L SatoDirectorSale plan200$9.98$2KForm 4
Mar 2, 2026Vicki L SatoDirectorSale plan21,800$9.50$207KForm 4
Feb 25, 2026Mark EisnerVice presidentSale plan1,889$9.82$18.5KForm 4
Feb 25, 2026Verneuil Vanina deVice presidentSale plan13,700$9.82$135KForm 4
Feb 24, 2026Vicki L SatoDirectorSale plan42,177$9.75$411KForm 4
Feb 24, 2026Vicki L SatoDirectorSale plan200$10.26$2.1KForm 4
Feb 24, 2026Brent SabatiniVice presidentSale plan1,430$9.53$13.6KForm 4
Feb 24, 2026Jason O'ByrneCFOSale plan1,634$9.53$15.6KForm 4
Feb 24, 2026Mark EisnerVice presidentSale plan1,616$9.53$15.4KForm 4
Feb 24, 2026Verneuil Vanina deVice presidentSale plan3,117$9.53$29.7KForm 4
Feb 24, 2026Backer Marianne DeCEOSale plan14,762$9.53$141KForm 4
Feb 23, 2026Brent SabatiniVice presidentSale plan1,829$7.45$13.6KForm 4
Feb 23, 2026Jason O'ByrneCFOSale plan2,089$7.45$15.6KForm 4
Feb 23, 2026Verneuil Vanina deVice presidentSale plan4,445$7.45$33.1KForm 4
Feb 23, 2026Backer Marianne DeCEOSale plan19,039$7.45$142KForm 4
Feb 13, 2026Brent SabatiniVice presidentSale plan1,530$7.79$11.9KForm 4
Feb 2, 2026Vicki L SatoDirectorSale plan22,000$7.71$170KForm 4
Jan 2, 2026Vicki L SatoDirectorSale plan22,000$5.93$130KForm 4
Dec 1, 2025SVF Endurance (Cayman) Ltd +210% ownerSale plan191,854$5.98$1.1MForm 4
Dec 1, 2025Vicki L SatoDirectorSale plan22,000$6.00$132KForm 4
Nov 28, 2025Softbank Vision Fund (Aiv M1) L.P. +210% ownerSale plan61,493$6.44$396KForm 4
Nov 26, 2025Softbank Vision Fund (Aiv M1) L.P. +210% ownerSale plan127,938$6.39$818KForm 4
Nov 25, 2025SVF Endurance (Cayman) Ltd +210% ownerSale plan235,971$6.38$1.5MForm 4
Nov 24, 2025SVF Endurance (Cayman) Ltd +210% ownerSale plan227,803$6.15$1.4MForm 4
Nov 17, 2025Jason O'ByrneCFOSale plan6,799$5.56$37.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
SVF Endurance (Cayman) Ltd10% owner–$4.1MDec 1, 2025
Vicki L SatoDirector–$1.5MMay 1, 2026
Softbank Vision Fund (Aiv M1) L.P.10% owner–$1.2MNov 28, 2025
Backer Marianne DeChief Executive Officer, Director–$947KApr 6, 2026
Verneuil Vanina deEVP, General Counsel, Corp Sec–$239KNov 3, 2026
Brent SabatiniSVP, Chief Accounting Officer–$113KJun 1, 2026
Jason O'ByrneEVP & Chief Financial Officer–$68.9KFeb 24, 2026
Mark EisnerEVP and Chief Medical Officer–$34KFeb 25, 2026
Janet NapolitanoDirector–$30.2KJun 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VIR short interest

Moderate short interest. 9.9% of VIR shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short barely changed.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 16.87M VIR shares were sold short, 9.9% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 11.9 trading days (days to cover).

Shares short, % of all shares

9.85%May 15Oct 3013.2%

Days to cover

11.9May 15Oct 3014.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202616.87M9.85%+4%1.42M11.9
Oct 15, 202616.24M9.60%+8%2.35M6.9
Sep 30, 202614.98M8.85%-24%2.14M7.0
Sep 15, 202619.66M11.62%-8%2.08M9.5
Aug 31, 202621.34M12.61%+9%1.92M11.1
Aug 14, 202619.60M11.58%+3%1.44M13.6
Jul 31, 202619.04M11.25%+3%1.56M12.2
Jul 15, 202618.45M10.94%-4%1.54M12.0
Jun 30, 202619.19M11.38%+6%3.21M6.0
Jun 15, 202618.08M10.72%-1%1.52M11.9
May 29, 202618.32M10.86%+9%1.69M10.8
May 15, 202616.83M9.98%+4%1.54M10.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Vir Biotechnology company events

Vir Biotechnology filed 18 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementECLIPSE 1 TLR Certain data from the ongoing Phase 3 ECLIPSE 1 clinical trial, including the ECLIPSE 1 TLR, were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ®, in Denver, Colorado on November 8, 2026. Filing
  2. Nov 4, 2026ResultsReleased financial results. Filing
  3. Oct 28, 2026LeadershipThe Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from eight to nine members and the appointment of Suzanne Topalian, M.D., to fill the… Filing
  4. Oct 14, 2026AnnouncementVir Bio issued a press release announcing the entry into the Agreement and the SPA. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. Filing
  5. Oct 8, 2026AnnouncementVir Biotechnology, Inc. (the Company) issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate… Filing
  6. Oct 1, 2026LeadershipVir Biotechnology, Inc. (the Company) announced that Aziz Sawaf, MBEE, MBA, CFA has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 5, 2026 (the Effective Date). Filing
  7. Aug 5, 2026ResultsReleased financial results. Filing
  8. Jul 24, 2026LeadershipJason O’Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed Vir Bio that he will be stepping down from his role, effective August 3, 2026, to pursue another opportunity. Filing
  9. Jun 10, 2026LeadershipThe Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from seven to eight members and the appointment of Timothy Coughlin, CPA, to fill the… Filing
  10. May 28, 2026LeadershipSaira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of… Filing
  11. May 6, 2026ResultsReleased financial results. Filing
  12. Apr 10, 2026LeadershipMark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026. Filing
  13. Mar 4, 2026LeadershipThe Board of Directors of Vir Biotechnology, Inc. (Vir Bio) appointed Marianne De Backer, M.Sc., Ph.D., MBA, Vir Bio’s Chief Executive Officer and principal executive officer, to the additional position of President. Filing
  14. Mar 2, 2026AnnouncementAs previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on February 26, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group… Filing
  15. Feb 26, 2026AgreementVir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters)… Filing
  16. Feb 23, 2026AgreementVir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement). Filing
  17. Jan 12, 2026ResultsReleased financial results. Filing
  18. Dec 16, 2025AgreementVir Biotechnology, Inc. (Vir Bio) and Norgine Pharma UK Limited (together with its affiliates in the Norgine group of companies, Norgine) entered into a License Agreement (the Agreement) with respect to certain commercial rights to the combination of tobevibart, an investigational monoclonal… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vir Biotechnology financials

Famous investors that hold VIR

4 of the 50 well-known investors we track reported holding VIR in their latest 13F filing. The largest position is Steve Cohen's, worth $75.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20266.77M$75.7M0.1%+20%
Ken Griffin · Citadel AdvisorsQ3 2026402,546$4.5M0.0%-59%
Jim Simons · Renaissance TechnologiesQ3 2026395,964$4.4M0.0%-61%
Israel Englander · Millennium ManagementQ3 202620,415$228K0.0%-57%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named VIR in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G4.6%
Nov 10, 2026STATE STREET CORPORATION13G4.6%
Nov 6, 2026ARCH Venture Fund IX, L.P.13D/A6.9%
Nov 6, 2026ARCH Venture Fund IX, L.P.13D/A6.9%
Oct 27, 2026BlackRock, Inc.13G/A12.4%
Oct 27, 2026BlackRock, Inc.13G/A12.4%

Questions about Vir Biotechnology, Inc. (VIR) stock

Who owns the most VIR stock?

The largest reported owner of Vir Biotechnology, Inc. (VIR) is BlackRock, Inc., with 12.3% of the company. In total, 235 funds and institutions reported holding VIR at the end of Q2 2026, together about 88% of the shares. See the largest owners.

Are VIR insiders buying or selling?

In the last 12 months, VIR insiders reported no open-market purchases and 33 sales worth $8.2M. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in VIR?

As of Oct 30, 2026, 16.87M VIR shares were sold short, 9.9% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 11.9 trading days (days to cover). See the history.

Which famous investors hold VIR?

4 of the 50 well-known investors we track reported VIR in their latest 13F filing, including Steve Cohen, Ken Griffin, Jim Simons. The largest position is worth $75.7M. See all holders.

Executive pay

Vir Biotechnology's chief executive was paid a total of $7.8M for the year ended Dec 31, 2025. In the last 12 months, Vir Biotechnology's executives and directors bought no stock on the open market and sold $2.9M.

Chief executive, total pay$7.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.